Venture capital fund
Every published round Breakout Labs took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Breakout Labs has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Breakout Labs, as distinct from the investments it has made.
Companies Breakout Labs has backed that another company then bought. An exit for the holding, not a deal Breakout Labs did.
Stories naming Breakout Labs. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Glyscend has begun a Phase 1 trial in South Australia for its oral polymer diabetes therapy and presented preclinical data; its US$20.5 million Series A was led by Santé Ventures and Brandon Capital.
Glyscend Therapeutics has begun a Phase 1 trial in South Australia of its oral polymer therapy for type 2 diabetes; the piece recalls its US$20.5m Series A led by Santé Ventures and Brandon Capital.